Xencor, Inc Deferred Income Tax Liabilities, Net
Xencor, Inc (XNCR) had Deferred Income Tax Liabilities, Net of $65.00 thousand as of 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2017-03-01
- 2016-12-31: Deferred Income Tax Liabilities, Net $65.00K.
- 2016-09-30: Deferred Income Tax Liabilities, Net $400.00K.
- 2016-06-30: Deferred Income Tax Liabilities, Net $1.78M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2016-12-31 | $65.00K 10-K · filed 2017-03-01 |
| 2016-09-30 | $400.00K 10-Q · filed 2016-11-02 |
| 2016-06-30 | $1.78M 10-Q · filed 2016-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |